GAMMA Investing LLC Lowers Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

GAMMA Investing LLC decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 44.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 241 shares of the company’s stock after selling 189 shares during the quarter. GAMMA Investing LLC’s holdings in Krystal Biotech were worth $38,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of KRYS. Segall Bryant & Hamill LLC boosted its stake in Krystal Biotech by 352.4% in the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after acquiring an additional 122,407 shares in the last quarter. State Street Corp grew its holdings in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares during the period. Franklin Resources Inc. boosted its position in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares in the last quarter. Braidwell LP lifted its position in shares of Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after acquiring an additional 61,512 shares during the period. Finally, Public Sector Pension Investment Board acquired a new position in Krystal Biotech during the second quarter worth about $10,037,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 5.1 %

Shares of NASDAQ KRYS opened at $142.64 on Wednesday. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The company has a market cap of $4.10 billion, a PE ratio of 80.59 and a beta of 0.85. The stock has a 50 day simple moving average of $173.55 and a 200-day simple moving average of $182.87.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Sell-side analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. Chardan Capital reissued a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup lifted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $206.67.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).